US FDA approves Arcutis' drug to treat chronic skin disease (updated)

Arcutis Biotherapeutics

15/12/2023 22:19

(Adds details on the approved drug in paragraphs 2-4)
       Dec 15 (Reuters) - The U.S. Food and Drug Administration
(FDA) on Friday approved Arcutis Biotherapeutics'  ARQT.O  drug
for treating a skin condition called seborrheic dermatitis in
individuals nine years of age and older.
    The health regulator's nod makes roflumilast foam the first
topical drug for treating moderate to severe seborrheic
dermatitis with a new mechanism of action in over two decades,
according to the company. 
    Seborrheic dermatitis, a common, chronic and recurrent
inflammatory skin disease, affects more than 10 million people
in the U.S., Arcutis said.
    The drug is a foam-based formulation of the company's
roflumilast cream 0.3%, sold as Zoryve, which is approved in the
U.S. as a topical treatment of plaque psoriasis in patients 6
years of age and older. 
    
    
    

 (Reporting by Pratik Jain in Bengaluru; Editing by Shailesh
Kuber and Krishna Chandra Eluri)
 ((Pratik.Jain@thomsonreuters.com;))